# 1 Dengue in Cambodia 2002-2020: Cases, Characteristics and Capture by

## 2 National Surveillance

- 3 Christina Yek<sup>1</sup>, Yimei Li<sup>2</sup>, Andrea R. Pacheco<sup>3</sup>, Chanthap Lon<sup>3</sup>, Veasna Duong<sup>4</sup>, Philippe
- 4 Dussart<sup>4#</sup>, Sophana Chea<sup>3</sup>, Sreyngim Lay<sup>3</sup>, Somnang Man<sup>3</sup>, Souv Kimsan<sup>5</sup>, Chea Huch<sup>5</sup>, Rithea
- 5 Leang<sup>5</sup>, Rekol Huy<sup>5</sup>, Cara E. Brook<sup>2</sup>, Jessica E. Manning<sup>6</sup>
- 6 <sup>1</sup>Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda,
- 7 MD, USA
- <sup>8</sup> <sup>2</sup>Department of Ecology and Evolution, University of Chicago, Chicago, IL, USA
- 9 <sup>3</sup>International Center of Excellence in Research, National Institute of Allergy and Infectious
- 10 Diseases, Phnom Penh, Cambodia
- <sup>4</sup>Virology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia
- <sup>5</sup>National Center of Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom
- 13 Penh, Cambodia
- <sup>6</sup>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious
- 15 Diseases, Rockville, MD, USA
- 16 # Present address: Institut Pasteur de Madagasacar, Antananarivo, Madagascar
- 17

#### 18 **Corresponding author:**

- 19 Jessica Manning
- 20 Email: jessica.manning@nih.gov
- 21 Mailing address: 12735 Twinbrook Parkway 2E-32A, Rockville, MD 20852
- 22 Telephone: +1 240 731 4938
- 23
- 24 Running title: Dengue Epidemiology in Cambodia
- 25 Keywords: Dengue, Cambodia, Disease Surveillance, Demographic Transitions
- 26 Word count: Abstract 225; Manuscript 3071
- 27 Figures: 3 Tables: 2

### 28 Abstract

29

#### 30 **Objective**

31 Data from 19 years of national dengue surveillance in Cambodia (2002-2020) were analyzed to

- 32 describe trends in dengue case characteristics and incidence.
- 33

### 34 Methods

35 Generalized additive models were fitted to dengue case incidence and characteristics (mean age,

36 case phenotype, fatality) over time. Dengue incidence in a pediatric cohort study (2018-2020)

37 was compared to national data during the same period to evaluate disease under-estimation by

38 national surveillance.

39

## 40 Findings

- 41 During 2002-2020, there were 353,270 cases of dengue (average age-adjusted incidence 1.75
- 42 cases/ 1,000 persons/ year) recorded in Cambodia, with an estimated 2.1-fold increase in case
- 43 incidence between 2002 and 2020 (slope = 0.0058, SE = 0.0021, p = 0.006). Mean age of
- 44 infected individuals increased from 5.8 years in 2002 to 9.1 years in 2020 (slope = 0.18, SE =

45 0.088, p < 0.001); case fatality rates decreased from 1.77% in 2002 to 0.10% in 2020 (slope = -

46 0.16, SE = 0.0050, p < 0.001). When compared to cohort data, national data under-estimated

47 clinically apparent dengue case incidence by 5.0-fold (95% CI 0.2 – 26.5), and overall dengue

48 case incidence (both apparent and inapparent cases) by 33.6-fold (range: 18.7-53.6).

49

### 50 Conclusion

- 51 Dengue incidence in Cambodia is increasing and disease is shifting to older pediatric
- 52 populations. National surveillance continues to under-estimate case numbers. Future
- 53 interventions should account for disease under-estimation and shifting demographics for scaling
- 54 and to target appropriate age groups.

### 55 Introduction

The global incidence of dengue is on the rise. Cases increased by 8-fold over the last two decades, with the greatest number of cases recorded in 2019.<sup>1</sup> Experts attribute this trend to a variety of viral, vector, host, and ecologic factors including high rates of population growth in endemic areas, rapid unplanned urbanization without simultaneous expansion of vector control and water management systems, increasing global connectivity, and climate change expanding the geographic range of the *Aedes spp*. mosquito, among others.<sup>2</sup>

62

63 Accurate estimates of dengue burden are crucial to ensure appropriate allocation of resources to 64 contain infection and manage clinical disease. The development of novel quadrivalent vaccines 65 has added urgency to the task as public health entities plan vaccine rollouts in dengue-endemic areas.<sup>3–5</sup> However, the most heavily-afflicted countries rely on resource-scarce national 66 67 surveillance systems with predominantly clinicosyndromic case identification and passive reporting, leading to gross under-estimation of disease burden.<sup>6</sup> One approach to this issue 68 69 involves drawing data from active cohort surveillance and applying an expansion factor (i.e., the 70 ratio of detected dengue cases to those in official reports) to estimate true incidence within the overall population.<sup>6</sup> However, most active surveillance studies rely on the detection of 71 72 symptomatic cases at select diagnostic centers, overlooking the majority of people that may have 73 clinically inapparent infection or do not seek care for other reasons.<sup>7</sup> Capturing this population of 74 inapparent cases is vital to understand disease pathogenesis and host immunity, and importantly, for design and evaluation of containment strategies.<sup>8</sup> Cross-sectional serosurveillance of dengue 75 76 captures prior infection, both clinically apparent and inapparent. Where age-stratified data is 77 available, this can be used to calculate transmission intensity (i.e., force of infection, defined as the rate at which susceptible individuals become infected) with practical applications including 78 defining target populations for pre-vaccination serologic screening.<sup>9</sup> Serosurveillance studies 79 applying techniques such as plaque reduction neutralization assays (PRNT) can provide 80 serotype-specific granularity and are less subject to cross-reactivity with other endemic 81 flaviviruses than ELISA-based serologic assays.<sup>10</sup> Finally, longitudinal serosurveillance provides 82 83 the most accurate capture by removing assumptions about incidence rate constancy over time or 84 age group. However, such methods are resource-intensive and impractical to guide public policy at a national level.<sup>11</sup> 85

86

87 The World Health Organization (WHO) region of Southeast Asia (SEA) includes ten dengueendemic countries that comprise 70% of dengue cases worldwide.<sup>1</sup> Among these is Cambodia, a 88 89 country in the Indochinese peninsula with a population of 17 million. National dengue surveillance data for Cambodia was last published in 2010.<sup>12</sup> This report covered a period of 90 dynamic change from 1980 to 2007 during which post-civil war improvements in public health 91 92 infrastructure led to improved surveillance efforts including several sentinel sites in the early 93 2000s. Since the publication of this report, Cambodia has continued to undergo marked changes 94 in population demographics and urbanization. However, national dengue surveillance continues 95 to have several limitations including reliance on self-referral, predominant clinicosyndromic 96 identification, exclusion of private sector practices, and a largely passive reporting system 97 dependent on variable participation of provincial facilities. The true incidence of disease is 98 significantly under-estimated by national data: two studies conducted in central Cambodia 99 between 2006 and 2008 extrapolated expansion factors from single-province active surveillance 100 and described under-estimation of total dengue cases by national surveillance methods ranging from 3.9- to 29.0-fold.<sup>13,14</sup> With novel interventions and vaccines on the horizon, it is paramount 101 102 to improve estimates of dengue burden in countries such as Cambodia to better guide 103 containment strategies and vaccine rollout campaigns. 104 105 In this report we analyze nearly two decades of Cambodian national dengue surveillance data

106 from 2002 through 2020 and compare findings to those derived from a longitudinal pediatric

107 cohort study to describe recent trends in dengue case characteristics and incidence.

#### 108 Methods

#### 109 National Surveillance for Dengue Cases

110 The Cambodia National Dengue Control Program collects monthly data on hospitalized dengue 111 cases at public healthcare facilities. WHO clinical case definitions are applied to make a clinical 112 diagnosis of dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome 113 (DSS). Serologic confirmatory testing is performed in a minority of cases using the SD 114 BIOLINE Dengue Duo rapid test (Abbott®), depending on the patient's ability to afford the test 115 and the availability of test kits. In addition, the Virology Unit at Institut Pasteur du Cambodge 116 confirms dengue serotype using a specific RT-PCR in a subset of patient samples submitted by sentinel sites.<sup>15</sup> Sentinel surveillance was introduced in 5 provinces in 2001, with subsequent 117 118 expansion to 10 provinces in 2020 and 15 provinces in 2021. Patients are treated according to the Cambodian National Guidelines for Clinical Management of Dengue 2018.<sup>16</sup> 119 120

121 Census Data

122 Census data was obtained from the 1998, 2008, and 2019 national Cambodian population census.

Population growth rate was computed using the exponential growth formula to extrapolate data
 for inter-census years.<sup>17</sup>

125

126 Pediatric Cohort Study

127 A prospective longitudinal cohort study of 771 children aged two to nine years was conducted in 128 the province of Kampong Speu, Cambodia to investigate the relationship between dengue infection and host immunological response to Ae. aegypti mosquito saliva (NCT03534245).<sup>18</sup> 129 130 Children were followed semi-annually from July 2018 through September 2021 with serial 131 serologic testing using dengue IgG ELISA (PanBio Dengue Indirect IgG, Abbott Laboratories) and PRNT, as previously described.<sup>18</sup> Children who developed symptoms consistent with acute 132 dengue were evaluated as unscheduled sick visits, during which rapid dengue testing (SD Bioline 133 134 DengueDuo NS1 Ag/immunoglobulin M [IgM]/IgG) was performed followed by confirmatory 135 dengue PCR. Clinically inapparent cases of dengue were identified, defined as children who had 136 negative dengue IgG ELISA at baseline and developed mono- or multitypic immunity (PRNT<sub>50</sub> 137 >1:40) during the study period. There was moderate loss to follow-up from mid-2020 onwards as

a result of the global COVID-19 pandemic; due to paucity of data during this period, data was
 censored at the 4<sup>th</sup> study visit in April 2020.

140

141 Study Oversight and Ethics Statement

National dengue surveillance data used in this study were de-identified and are publicly available
by request from the Cambodian Ministry of Health. Monthly dengue incidence is also accessible
via WHO weekly reports.<sup>19</sup> The U.S. National Institutes of Health and the National Ethics
Committee on Human Research in Cambodia gave ethical approval for this work (pediatric
protocol NCT03534245).

147

### 148 Statistical Analysis

149 Crude dengue case data were collected from January 2002 to December 2020. Overall case and 150 age-specific incidence rates were calculated using population data derived from 1998, 2008, and 151 2019 census (as above). Age-adjusted incidence was calculated by multiplying age-specific 152 incidence and weighting of each age strata derived from 1998 census data.<sup>12</sup> Longitudinal trends 153 in dengue incidence, demographics, and case characteristics were explored using generalized 154 additive models fitted to annual case data, with a monthly smoothing term (Supplemental Text 155 S1). Two expansion factors were calculated by comparing dengue incidence in the pediatric 156 cohort to that reported via national surveillance. Expansion factor 1  $(EF_{1})$  represented under-157 detection of clinically apparent dengue and was calculated by determining the average incidence 158 rate ratio of apparent dengue cases detected through active febrile surveillance in the pediatric 159 cohort  $(P_A)$  to that detected by national surveillance during July 2018-April 2020 for the same 160 age group (children aged 2-9 years) living in Kampong Speu ( $P_N$ ). This was performed by fitting 161 a Poisson generalized linear model via quasilikelihood to allow for variance inflation, adjusting 162 for month as a categorical variable. Expansion factor 2  $(EF_2)$  represented under-detection of both 163 clinically apparent and inapparent dengue and was calculated by dividing the cumulative 164 incidence of apparent and inapparent dengue cases detected at semi-annual surveillance 165 timepoints in pediatric cohort  $(P_T)$  by semi-annual cumulative incidence of dengue cases in the 166 corresponding age group in Kampong Speu detected by national surveillance ( $P_{N6}$ ). Statistical 167 analyses were performed in R (version 4.1.0).

#### 168 **Results**

169 Nationally Reported Dengue Incidence in Cambodia 2002-2020

Cases of dengue across 25 Cambodian provinces were reported on a weekly basis and collated in
a central database. Over 19 years of national surveillance, a total of 353,270 cases were reported,

- 172 corresponding to an average age-adjusted incidence of 1.75 cases/ 1,000 persons/ year (Table 1).
- 173 Major epidemics occurred in 2007, 2012, and 2019 (Figure 1A). The 2019 epidemic was the
- 174 largest since national surveillance was implemented in 1980, with an annual total of 68,597 cases
- 175 (age-adjusted incidence 6.27 cases/ 1,000 persons/ year), a 3.91-fold increase from the average
- across prior years and a 1.64-fold increase from the average in other epidemic years (2007,
- 177 2012). Annual peaks in dengue cases occurred in June through August, coinciding with the
- 178 country's annual wet season and periods of heavy rainfall (Figure 1B).<sup>20</sup> Siem Reap and Phnom
- 179 Penh provinces reported the highest case incidence (average 3.00 and 2.03 cases/ 1,000 persons/
- 180 year, respectively) (Supplementary Figure 1). Generalized additive models were fitted to dengue
- 181 cases from 2002 to 2020 and demonstrated a significant increase in both crude case numbers
- 182 (slope = 0.042, SE = 0.00031, p <0.001) and age-adjusted incidence (slope = 0.0058, SE =
- 183 0.0021, p = 0.006), representing a 2.1-fold increase in both metrics over the 19-year period
- 184 (Figure 2 and Supplementary Table 1).
- 185

# 186 Changes in Dengue Case Characteristics Over Time

- 187 Dengue cases were evenly distributed by gender (51% male, 49% female), and mean age of
- 188 infected individuals across the entire period was 7.7 years (SD 5.8). In a generalized additive
- 189 model, predicted mean age of infected individuals increased significantly from 5.8 years (SE 0.3)
- 190 in 2002 to 9.1 years (SE 0.4) in 2020 (slope = 0.18, SE = 0.0088, p < 0.001; Figure 3A and
- 191 Supplementary Table 1). The trend of increasing age with time was sustained within different
- 192 case phenotypes (dengue fever: slope = 0.17, SE = 0.011, p <0.001; dengue hemorrhagic fever:
- 193 slope = 0.20, SE = 0.0095, p <0.001; dengue shock syndrome: slope = 0.13, SE = 0.012, p
- 194 <0.001; Supplementary Figure 3). DF represented the majority (51%) of overall cases across the
- 195 entire study period, with DHF and DSS representing 45% and 4%, respectively. Average annual
- 196 case fatality rate was 0.57% (SD 0.48). Generalized additive models demonstrated decreasing
- 197 proportions of severe dengue among overall cases (DHF: 47.8% in 2002 to 42.6% in 2020, slope
- 198 = -0.012, SE = 0.00062, p <0.001; DSS: 6.7% in 2002 to 2.3% in 2020, slope = -0.061, SE =

199 0.0016, p < 0.001), and decreasing case fatality rates (1.77% in 2002 to 0.10% in 2020, slope = -200 0.16, SE = 0.0050, p < 0.001) from 2002 to 2020 (Figure 3B-D and Supplementary Table 1). 201 Dengue serotype-specific RT-PCR was performed on a monthly basis in a subset of cases from 202 sentinel sites. Across all years, DENV-2 was the most prevalent serotype (37.1%) followed by 203 DENV-1 (32.2%), DENV-3 (22.6%), and DENV-4 (8.1%). There was significant yearly 204 variation: the 2007 major epidemic was predominantly driven by DENV-3, while subsequent years saw alternating DENV-1 and DENV-2 predominance including the 2012 epidemic driven 205 206 by DENV-1 and the 2019 epidemic driven by a mix of DENV-1 and DENV-2 (Supplementary 207 Figure 3).

208

#### 209 Comparisons of Data from National Surveillance Data and a Longitudinal Cohort Study

In July 2018, 771 children aged 2 to 9 years living in the province of Kampong Speu were
enrolled in a community-based pediatric cohort study.<sup>18</sup> Between July 2018-April 2020, a total of

212 51 clinically apparent, laboratory-confirmed dengue cases were identified (average monthly

213 incidence  $(P_A)$  of 3.0 per 1,000 persons (range: 0-22.0)) (Table 2). During the same period,

national surveillance captured an average monthly incidence  $(P_N)$  of 0.6 per 1,000 persons

215 (range: 0.01-2.4) in the same age group and in the same province. The average case incidence

ratio of  $P_A: P_N$  was calculated to give an expansion factor ( $EF_1$ ) of 5.0 (95% CI 0.2-26.5). Among

217 597 children identified as immunologically naïve to dengue infection based on PRNT data at

218 baseline assessment, there were a total of 148 cases of clinically inapparent seroconversions

219 identified during July 2018-April 2020. The cumulative incidence of all dengue cases ( $P_T$ ;

including both clinically apparent and inapparent cases) in the cohort was calculated at each 6-

221 monthly study interval (average 6-monthly cumulative incidence 135.9 cases per 1,000 persons,

range: 44.7-239.4) and compared to the corresponding 6-monthly cumulative incidence of

apparent dengue cases detected by national surveillance ( $P_{N6}$ ; average 4.4 cases per 1,000

persons, range: 2.3-8.4); the ratio of  $P_T$ :  $P_{N6}$  gave an expansion factor ( $EF_2$ ) of 33.6 (range: 18.7-

225 53.7).

#### 227 Discussion

228 Cambodia is in a dramatic state of change with accelerated rural-to-urban migration, climate 229 change, land-use transformation, infrastructure development, and demographic and socio-230 economic shifts within its population. The dynamic milieu affects transmissibility of vector-231 borne disease and poses challenges to accurate modeling of dengue burden in this hyper-endemic 232 country. Data from 19 years of national dengue surveillance in Cambodia show a greater than 233 two-fold increase in dengue from 2002-2020, and a shift in the bulk of disease burden to older 234 pediatric age groups. When compared with data from a local longitudinal pediatric cohort, 235 national surveillance appears to under-estimate incidence by 5.0-fold for clinically apparent 236 cases and 33.6-fold for both apparent and inapparent cases in Kampong Speu province. 237 Dengue is also increasing in other areas of Southeast Asia.<sup>2,21</sup> Understanding the root causes of 238 239 disease expansion can be challenging in countries where national surveillance is passive and 240 inconsistent. While changes in surveillance practices could contribute to an apparent increase in 241 cases, our comparison of national data with local cohort surveillance in 2018-2020 demonstrated 242 comparable underreporting of dengue burden with that identified in previous work from earlier years.<sup>13,14</sup> If we assume that national dengue reporting systems in Cambodia have remained fixed 243

243 years. <sup>111</sup> If we assume that national dengue reporting systems in Cambodia have remained fixed 244 through time, possible explanations for the observed increase in dengue cases from 2002-2020 245 include: i) a steady increase in susceptible hosts, such as due to population growth (though we 246 note that because dengue incidence increased as well, changes in population size alone cannot 247 explain the observed rise), and ii) an increase in transmission intensity, such as due to increasing 248 population density, a growing vector pool, altered vector/ host behavior leading to heightened 249 exposure, or evolving viral pathogenicity.<sup>22</sup> Most likely, there are multifold contributors, and a 250 multifaceted approach is needed to reduce transmission intensity.

251

We noted a concurrent increase in mean age of dengue infection in Cambodia between 2002 and 2020, predominantly driven by an increase in age-specific incidence in the 10-14 year age group. This effect may be underestimated due to poor clinical recognition of dengue cases in nonpediatric populations in Cambodia.<sup>23</sup> The shift of dengue to older populations has been described in other SEA countries and attributed to demographic transitions resulting from

257 industrialization.<sup>9,24,25</sup> However, changes in the age distribution of the overall population alone

258 are unlikely to account for this shift, as even within age strata we noted different behavior of age-259 specific incidence with time: for example, incidence was stagnant or decreasing for ages <10260 years but increasing for ages 10-14 years. More likely, socioeconomic development leading to 261 altered human behavior and vector habitats may have moved the host:vector interface away from 262 the home and into public spaces such as schools and workplaces. Dengue has been classically 263 described as a disease of the young, but recent trends may indicate the need for a paradigm shift. 264 Recognizing the changing demographic of dengue, it is critical that interventions such as vaccination be planned using accurate age-specific data to identify appropriate target 265 266 populations.

267

268 Disease under-detection is a problem in most dengue-endemic countries and various modeling methods have been proposed to address the issue.<sup>6,7,26</sup> Two previous studies aimed to measure 269 270 the degree of under-estimation of clinically apparent dengue in Kampong Cham province, Cambodia, between 2006 and 2008. They found 9.1-fold<sup>13</sup> and 3.9 to 29.0-fold (variation by 271 vear)<sup>14</sup> more symptomatic dengue cases detected with active surveillance of pediatric cohorts 272 273 compared to national data, respectively. Neither study examined inapparent infection. Here, we 274 applied data from a pediatric cohort in Kampong Speu province and found a 5.0-fold higher rate 275 of clinically apparent dengue in cohort versus national data between 2018 and 2020. Varying 276 rates of dengue and quality of healthcare infrastructure among provinces and over time are 277 among multiple factors affecting surveillance fidelity – this is reflected by the wide variation of expansion factors reported here and elsewhere.<sup>6</sup> An additional finding from our cohort was the 278 279 high incidence of clinically inapparent dengue, accounting for an additional 6-fold 280 underestimation of total case numbers. Ultimately, accurate capture of both clinically apparent 281 and inapparent dengue is needed, for instance, to identify areas with high transmission that could 282 benefit from vector control or populations with monotypic immunity for vaccination. Febrile and serologic surveillance should occur in tandem to inform public health interventions.<sup>26</sup> 283

284

Dengue control is a global health priority.<sup>1</sup> Fortunately, despite increasing dengue incidence in
Cambodia over the past two decades, the proportion of severe manifestations of dengue and case
fatality rates have declined. This is likely due to socioeconomic progress leading to improving
overall population health (increased access to care, fewer co-morbidities). Additionally, the

289 National Dengue Control Program has focused on intensive education and in-service campaigns

290 for nurses and doctors over the last few years,<sup>27</sup> and has urged treatment of dengue patients

within the decentralized national health system instead of at unregulated private practices.<sup>16</sup>

292 These improvements may have enabled earlier recognition and appropriate management of cases,

and are overall an encouraging sign that public health efforts in Cambodia are producing positiveresults.

295

This study has several limitations. Effects of climate, migration, changing surveillance practices, advances in clinical knowledge, improvements in health infrastructure, and periodic boosting of

298 public and provider awareness could not be accounted for given inconsistent collection of these

299 data over the 19-year period. The last comprehensive assessment of dengue epidemiology in

300 Cambodia included an evaluation of vector control, but this analysis could not be repeated due to

301 limited updated data.<sup>12</sup>

302

# 303 Conclusion

The incidence of dengue in Cambodia has increased significantly over the past two decades and disease burden is shifting to older pediatric populations. True burden continues to be underestimated, although there have been notable successes of national programs reflected by a reduction in cases of severe dengue and case fatality rates. Future interventions such as vaccine campaigns or vector control will need to account for under-estimation and shifting demographics to target susceptible populations at the appropriate scale.

310

### 311 Acknowledgements

312 The authors would like to acknowledge the staff at the National Dengue Control Program and the

313 National Center of Parasitology, Entomology, and Malaria Control in Cambodia for their

314 contributions to dengue surveillance, control, and reporting.

315

# 316 Funding Statement

317 This study was funded in part by the Intramural Research Program of the National Institute of

318 Allergy and Infectious Diseases at the National Institutes of Health (U.S.A.), and by the Merck

319 Investigator Studies Program (Award #60826).

320

# 321 Data Availability Statement

322 All data produced in the present study are available upon reasonable request to the authors.

#### 323 References

- World Health Organization. Dengue and severe dengue. World Health Organization,
   Geneva, 2021. Accessed August 31, 2021. https://www.who.int/news-room/fact sheets/detail/dengue-and-severe-dengue
- Simmons CP, Farrar JJ, Nguyen van VC, Wills B. Dengue. *N Engl J Med.* 2012;366(15):1423-1432. doi:10.1056/NEJMra1110265
- Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine
   Safety and Efficacy. *New England Journal of Medicine*. 2018;379(4):327-340.
   doi:10.1056/NEJMoa1800820
- Biswal S, Borja-Tabora C, Martinez Vargas L, et al. Efficacy of a tetravalent dengue
  vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3
  trial. *Lancet*. 2020;395(10234):1423-1433. doi:10.1016/S0140-6736(20)30414-1
- Kallas EG, Precioso AR, Palacios R, et al. Safety and immunogenicity of the tetravalent,
  live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind,
  randomised placebo-controlled phase 2 trial. *Lancet Infect Dis.* 2020;20(7):839-850.
  doi:10.1016/S1473-3099(20)30023-2
- Undurraga EA, Halasa YA, Shepard DS. Use of expansion factors to estimate the burden of
  dengue in Southeast Asia: a systematic analysis. *PLoS Negl Trop Dis*. 2013;7(2):e2056.
  doi:10.1371/journal.pntd.0002056
- Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis
  from the Global Burden of Disease Study 2013. *Lancet Infect Dis*. 2016;16(6):712-723.
  doi:10.1016/S1473-3099(16)00026-8
- Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological
   Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus
   Infections. *Front Immunol.* 2014;5:280. doi:10.3389/fimmu.2014.00280
- 348
  9. Katzelnick LC, Ben-Shachar R, Mercado JC, et al. Dynamics and determinants of the force
  349 of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. *Proc Natl Acad Sci*350 USA. 2018;115(42):10762-10767. doi:10.1073/pnas.1809253115
- 10. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
  ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
  prospective population-based study. *Lancet Glob Health*. 2021;9(1):e44-e51.
  doi:10.1016/S2214-109X(20)30392-2
- Reiner RC, Stoddard ST, Forshey BM, et al. Time-varying, serotype-specific force of
  infection of dengue virus. *Proc Natl Acad Sci U S A*. 2014;111(26):E2694-2702.
  doi:10.1073/pnas.1314933111

358 359 360	12.	Huy R, Buchy P, Conan A, et al. National dengue surveillance in Cambodia 1980–2008: epidemiological and virological trends and the impact of vector control. <i>Bulletin of the World Health Organization</i> . 2010;88(9):650. doi:10.2471/BLT.09.073908
361 362 363	13.	Wichmann O, Yoon IK, Vong S, et al. Dengue in Thailand and Cambodia: An Assessment of the Degree of Underrecognized Disease Burden Based on Reported Cases. <i>PLoS Negl Trop Dis</i> . 2011;5(3):e996. doi:10.1371/journal.pntd.0000996
364 365 366	14.	Vong S, Goyet S, Ly S, et al. Under-recognition and reporting of dengue in Cambodia: a capture-recapture analysis of the National Dengue Surveillance System. <i>Epidemiol Infect</i> . 2012;140(3):491-499. doi:10.1017/S0950268811001191
367 368 369	15.	Ou TP, Yun C, Auerswald H, et al. Improved detection of dengue and Zika viruses using multiplex RT-qPCR assays. <i>Journal of Virological Methods</i> . 2020;282:113862. doi:10.1016/j.jviromet.2020.113862
370 371 372 373	16.	Cambodian Ministry of Health. National Guideline for Clinical Management of Dengue (Version 3). Published online 2018. Accessed October 28, 2021. https://niph.org.kh/niph/uploads/library/pdf/GL055_National_guideline_for_ClM_Dengue.pdf
374 375	17.	The World Bank. World Development Indicators. Accessed October 29, 2021. https://databank.worldbank.org/metadataglossary/2/series/SP.POP.GROW
376 377 378 379	18.	Manning JE, Chea S, Parker DM, et al. Development of inapparent dengue associated with increased antibody levels to Aedes aegypti salivary proteins: a longitudinal dengue cohort in Cambodia. <i>J Infect Dis.</i> Published online October 27, 2021:jiab541. doi:10.1093/infdis/jiab541
380 381	19.	World Health Organization Regional Office for the Western Pacific. Dengue Situation Updates. Published online 2020. http://iris.wpro.who.int/handle/10665.1/14461
382 383	20.	Cousien A, Ledien J, Souv K, et al. Predicting Dengue Outbreaks in Cambodia. <i>Emerg Infect Dis.</i> 2019;25(12):2281-2283. doi:10.3201/eid2512.181193
384 385 386	21.	Du M, Jing W, Liu M, Liu J. The Global Trends and Regional Differences in Incidence of Dengue Infection from 1990 to 2019: An Analysis from the Global Burden of Disease Study 2019. <i>Infect Dis Ther</i> . 2021;10(3):1625-1643. doi:10.1007/s40121-021-00470-2
387 388	22.	Katzelnick LC, Coello Escoto A, Huang AT, et al. Antigenic evolution of dengue viruses over 20 years. <i>Science</i> . 2021;374(6570):999-1004. doi:10.1126/science.abk0058
389 390 391 392	23.	Bohl Jennifer A., Lay Sreyngim, Chea Sophana, et al. Discovering disease-causing pathogens in resource-scarce Southeast Asia using a global metagenomic pathogen monitoring system. <i>Proceedings of the National Academy of Sciences</i> . 2022;119(11):e2115285119. doi:10.1073/pnas.2115285119

393 394 395	24.	Cummings DAT, Iamsirithaworn S, Lessler JT, et al. The Impact of the Demographic Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical Modeling. <i>PLoS Med</i> . 2009;6(9):e1000139. doi:10.1371/journal.pmed.1000139
396 397 398	25.	Rodríguez-Barraquer I, Buathong R, Iamsirithaworn S, et al. Revisiting Rayong: Shifting Seroprofiles of Dengue in Thailand and Their Implications for Transmission and Control. <i>American Journal of Epidemiology</i> . 2014;179(3):353-360. doi:10.1093/aje/kwt256
399 400	26.	Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. <i>Nature</i> . 2013;496(7446):504-507. doi:10.1038/nature12060
401 402 403	27.	Handel AS, Ayala EB, Borbor-Cordova MJ, et al. Knowledge, attitudes, and practices regarding dengue infection among public sector healthcare providers in Machala, Ecuador. <i>Trop Dis Travel Med Vaccines</i> . 2016;2:8. doi:10.1186/s40794-016-0024-y
404	28.	Wood SN. Mgcv: GAMs and generalized ridge regression for R. R News. 2001;1(2):20-25.

# 406 **Tables and Figure Legends**

# Table 1: Demographic and Geographic Characteristics of Dengue Cases in Cambodia, 2002-2020

Chamataristia	All Years	2002-2007	2008-2013	2014-2020
Characteristic	(N=353,270)	(N=100,046)	(N=109,619)	(N=143,605)
Diagnosis, N (%)				
Dengue fever	180,914 (51)	50,334 (50)	50,719 (46)	79,861 (56)
Dengue hemorrhagic fever	158,536 (45)	44,278 (44)	54,437 (50)	59,821 (42)
Dengue shock syndrome	13,820 (4)	5,434 (5)	4,463 (4)	3,923 (3)
Case Fatality Rate, %	0.57	1.19	0.43	0.19
Gender, N (%)				
Male	178,996 (51)	49,119 (49)	54,849 (50)	75,028 (52)
Female	174,274 (49)	50,927 (51)	54,770 (50)	68,577 (48)
Age in Years, Mean (SD)	7.7 (5.8)	6.4 (3.9)	6.9 (4.5)	9.2 (7.4)
Age-Adjusted Incidence (per	1 75	1.57	1.76	1.90
1,000 persons per year)	1.75	1.57		
Age-Specific Incidence (1,000				
persons/ year)				
<1 year	3.95	3.48	4.25	4.10
1-4 years	3.65	4.19	3.97	2.91
5-9 years	5.06	4.73	5.44	5.01
10-14 years	2.96	2.08	2.53	4.07
15-19 years	0.37	0.12	0.22	0.71
20-24 years	0.10	0.01	0.03	0.23
25-39 years	0.05	0.00	0.02	0.11
>=40 years	0.02	0.00	0.01	0.06
Case Incidence by Province				
(1,000 persons/ year)				
Banteay Meanchey	1.91	1.75	2.30	1.72
Battambang	0.60	0.30	0.54	0.90
Kampong Cham*	1.10	1.49	1.20	0.68

Kampong Chhnang	1.14	0.90	1.12	1.36
Kampong Speu	1.19	1.37	1.31	0.93
Kampong Thom	1.85	1.56	1.74	2.19
Kampot	0.53	0.57	0.52	0.52
Kandal	1.88	2.11	1.89	1.69
Kep	0.80	0.72	0.45	1.15
Koh Kong	0.64	0.38	0.67	0.83
Kratie	0.43	0.46	0.32	0.50
Mondul Kiri	1.47	0.06	0.09	3.86
Otdar Meanchey	1.96	1.32	1.72	2.71
Pailin	1.41	0.21	1.02	2.77
Phnom Penh	2.03	1.87	1.55	2.57
Preah Sihanouk	1.11	0.57	0.65	1.96
Preah Vihear	1.49	0.35	1.34	2.61
Prey Veng	0.82	0.91	1.00	0.58
Pursat	0.26	0.19	0.30	0.30
Ratanak Kiri	0.64	0.26	0.25	1.29
Siem Reap	3.00	2.49	3.54	2.98
Stung Treng	0.47	0.56	0.18	0.63
Svay Rieng	0.49	0.68	0.38	0.41
Takeo	0.89	1.57	0.81	0.36

\*Including Tboung Khmum province, which was created from Kampong Cham province in 2013 and began reporting surveillance data from 2016

407

408 **Figure 1.** A) Annual dengue incidence in Cambodia, 2002-2020. Absolute dengue case numbers

409 represented by blue bars on the left y-axis, case incidence (cases/ 1,000 persons) represented by

410 the red line on the right y-axis. B) Monthly dengue case numbers in Cambodia, by year (2002-

411 2020), with colors corresponding to specific epidemic years vs. non-epidemic years, as indicated

412 by legend.

414 **Figure 2.** Generalized additive models (GAM) fitted to A) crude dengue case numbers and B)

415 age-adjusted dengue case incidence in Cambodia from 2002 and 2020. Black lines depict crude

416 cases (A) and age-adjusted incidence (B), respectively, while red line gives GAM projections

- 417 excluding the effect of month. Translucent red shading corresponds to 95% confidence intervals
- 418 by standard error.
- 419

420 **Figure 3.** Generalized additive models of A) mean age of infected individuals, B) proportion of

421 dengue hemorrhagic fever, C) proportion of dengue shock syndrome, and D) case fatality rate for

422 all dengue cases in Cambodia from 2002 to 2020. Black line depicts mean age of infected

423 individuals by month (A). Red lines depict GAM projections excluding the effect of month.

424 Translucent shading corresponding to 95% confidence intervals by standard error.

425

426 **Table 2:** Comparison of dengue case incidence in Kampong Speu province from cohort and

427 national data sets, July 2018-April 2020

	Monthly Incidence o	f Apparent	6-monthly Incidence of All Dengue		
Month	Dengue Cases (Cases/ 1000 persons)		Cases (Cases/ 1000 persons)		
ivionui	National	Cohort (P.)	National Surveillance		
	Surveillance (P <sub>N</sub> )		(P <sub>N6</sub> )		
Jul 2018	0.48	1.30			
Aug 2018	0.32	0.00			
Sep 2018	0.39	2.59			
Oct 2018	0.44	1.30			
Nov 2018	0.30	0.00			
Dec 2018	0.30	0.00			
Jan 2019	0.15	0.00	2.39	44.71	
Feb 2019	0.10	1.30			
Mar 2019	0.31	2.59			
Apr 2019	0.40	2.59			
May 2019	0.88	3.89			
Jun 2019	1.86	7.78			

Jul 2019	2.43	22.05		
Aug 2019	2.43	11.67	8.42	239.38
Sep 2019	0.95	5.19		
Oct 2019	0.60	1.30		
Nov 2019	0.31	1.30		
Dec 2019	0.17	0.00		
Jan 2020	0.11	0.00		
Feb 2020	0.08	1.30		
Mar 2020	0.01	0.00		
Apr 2020	0.06	0.00	2.31	123.66





